Partnership Opportunities

Progenra has developed a portfolio of novel first in class small molecules. Progenra welcomes industry partners to execute mutually beneficial licensing agreements for the company's small molecules portfolio assets and/or its UbiPro™ Drug Discovery Platform. Progenra wishes to continue working with academic institutions to further dissect the ubiquitin proteasome system. We also welcome discussions with commercial and academic entities on in-licensing technologies and/or compounds that are complementary to Progenra's internal development strategy.

Progenra’s business development team has worked successfully with a variety of companies and academic institutions to establish agreements that are compatible with our partner’s strategic focus and goals. Our expert discovery team and external network is capable of ensuring solutions to any problem.

Partnering with Progenra Includes:

  • Unparalleled expertise in the ubiquitin proteasome system
  • Small molecule drug candidate assets in
    • immune-oncology
    • inflammation
    • neurodegeneration
  • Access to all the tools and technology under Progenra's UbiPro™ Drug Discovery Platform on an exclusive or nonexclusive basis to identify and develop a modifier of a deubiquitylase or ligase for use as a therapeutic
  • Development of new targets within the ubiquitin-proteasome system for the identification of modifiers

Research collaboration with Progenra allows Progenra’s partners to overcome the greatest barriers to working in the ubiquitin field.

Please contact the Progenra Business Development Team for inquiries: bd@progenra.com